Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.67 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.67 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.58 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320783 | 0.88 | DRD2 (0.68) | CHRM2CHRM1CHRM3MTNR1AMTNR1B | |
| SCHEMBL10043011 | 0.88 | DRD2 (0.68) | CHRM2CHRM1CHRM3MTNR1AMTNR1B | |
| SCHEMBL3312782 | 0.88 | DRD2 (0.68) | CHRM2CHRM1CHRM3MTNR1AMTNR1B | |
| SCHEMBL24029258 | 0.86 | DRD2 (0.54) | CHRM2CHRM1CHRM3MTNR1AMTNR1B | |
| SCHEMBL4207562 | 0.82 | CHRM2 (0.66) | CHRM2CHRM1CHRM3MTNR1AMTNR1B | |
| SCHEMBL16233581 | 0.81 | CHRM2 (0.64) | CHRM2CHRM1CHRM3MTNR1AMTNR1B | |
| SCHEMBL20460429 | 0.81 | CHRM2 (0.52) | CHRM2CHRM1CHRM3MTNR1AMTNR1B | |
| SCHEMBL9345242 | 0.80 | ADRA1A (0.62) | CHRM2CHRM1CHRM3MTNR1AMTNR1B | |
| SCHEMBL8589055 | 0.80 | CHRM3 (1.00) | CHRM2CHRM1CHRM3DRD2DRD3 | |
| SCHEMBL4205695 | 0.80 | CHRM3 (1.00) | CHRM2CHRM1CHRM3DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2412372-A1 | 2-Aminooxazole derivatives for use as TRPV1 antagonists for treating i.a. pain, inflammation, neurodegenerative diseases or gastrointestinal diseases | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7998993-B2 | TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2220059-B1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | ABBOTT LAB (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20090124666-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124666-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV2, TRPV3 | CHRM2 200/4885CHRM1 199/4885CHRM3 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.